中国医学创新2025，Vol.22Issue(5)：175-179,5.DOI:10.3969/j.issn.1674-4985.2025.05.041
罗沙司他在治疗慢性肾脏病所致的贫血及其他适应证中的应用进展
Progress in the Application of Roxadustat in the Treatment of Anemia and other Indications Caused by Chronic Kidney Disease
刘倩倩 1李昕萌 1刘云启1
作者信息
- 1. 滨州医学院附属医院肾内科 山东 滨州 256603
- 折叠
摘要
Abstract
Roxadustat is a hypoxia-inducible factor-prolyl hydoxylase inhibitors(HIF-PHIs),which is a new oral formulation.It can effectively improve the anemia symptoms of dialysis and non-dialysis dependent chronic kidney disease(CKD)patients,and its curative effect is not inferior to the traditional treatment.The wide application of Roxadustat is not only reflected in the treatment of anemia caused by CKD,but also found to have new therapeutic effects in indications such as posttransplant anemia(PTA)and cardiovascular protection,which provides new possibilities and hopes for the treatment of other related diseases.In addition,the safety and adverse reactions of Roxadustat are also of concern.The purpose of this article is to describe Roxadustat in the treatment of anemia caused by CKD and other indications,in order to provide reference for clinical application.关键词
罗沙司他/慢性肾脏病/缺氧诱导因子脯氨酸羟化酶抑制剂/贫血/移植后贫血Key words
Roxadustat/Chronic kidney disease/Hypoxia-inducible factor-prolyl hydoxylase inhibitors/Anemia/Posttransplant anemia引用本文复制引用
刘倩倩,李昕萌,刘云启..罗沙司他在治疗慢性肾脏病所致的贫血及其他适应证中的应用进展[J].中国医学创新,2025,22(5):175-179,5.
